Results 51 to 60 of about 13,099 (221)

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Dempke, Wolfram, Linke, Rolf
core   +1 more source

Polycythemia vera masked due to severe iron deficiency anemia

Hematology/Oncology and Stem Cell Therapy, 2018
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin.
Shweta Kambali, Asma Taj
doaj   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

Annals of Oncology, 1999
In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements.Six patients with Ph-negative, BCR-ABL-positive CML were investigated.
D, Seong, H M, Kantarjian, M, Albitar, R, Arlinghaus, J, Xu, M, Talpaz, M B, Rios, J Q, Guo, S, O'Brien, M, Siciliano   +9 more
openaire   +2 more sources

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [PDF]

Leukemia, 2001
The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I trial (Druker et al 1999). Combination therapy may increase this proportion. We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea,
J, Topaly, W J, Zeller, S, Fruehauf
openaire   +2 more sources

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +1 more source

Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]

, 2007
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus, Jesus, Caroline Regina de   +1 more
core   +1 more source

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

, 2001
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA- associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CIVIL ...
Lill, JR, Christmas, SE, Wang, LH, Macintyre, AR, Bourdon, A, Hill, SC, Rojas, J, Dodi, IA, Bonner, PLR, Aubert, G, Creaser, CS, Clark, RE, Rees, RC, Travers, PJ, Madrigal, JA   +14 more
core   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Jørgensen, Heather G., Holyoake, T.L., Holyoake, T., Abed El Baky, Mohamed, Bartholomew, C., Melo, Junia V., Roy, P., Melo, J.V., Abed El Baky, M., Roy, S., Jørgensen, H., Jorgensen, H.G., Strathdee, G., Strathdee, Gordon, Melo, J., Roy, Swagata, Holyoake, Tessa L., Roy, Poornima, Bartholomew, Christopher   +18 more
core   +1 more source